NR3C2 and chronic kidney disease: Furthermore, Bakris et al. published recently that the addition of the non-steroidal mineralocorticoid receptor antagonist finerenone in HDM-2 patients with CKD already treated with maximum doses of either ACE-I or AT-1B induced a further decrease in risks of CKD progression and cardiovascular events [33].